HANSEN-TECHNOLOGIES
25.4.2024 12:01:33 CEST | Business Wire | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water, and communications industries, is pleased to announce that Stockholm Exergi, a major energy provider in Sweden, is the latest to join the growing community of Hansen Trade users. Enabled by Hansen Trade, Stockholm Exergi will commence operations in a balance responsible party role and leverage the platform to process all trading operations in physical power markets, including Day-Ahead, Intraday, and Ancillary Services market trading.
Hansen Trade enables Stockholm Exergi to participate in all marketplaces with an automated trading tool, with a modern, cloud-native, and modular design. For Day-Ahead trading, the solution delivers a streamlined bidding process, detailed trade-result handling, and comprehensive safety features, making it possible to optimise all assets in the marketplace without spending time on manual processing. The fully automated Intraday Trading capability handles balance management and available capacity optimisation for all assets, round-the-clock, with highly flexible and dynamic trading strategy tools. Furthermore, the Ancillary Services capability optimises capacity in the aFRR, mFRR, and FCR markets.
Erik Forsén, Product Owner for Ancillary Services at Stockholm Exergi, commented: “To be truly effective when trading in physical marketplaces requires modern, automated trading tools. Our decision to begin operating as a balance-responsible party reinforced the need for a platform to optimise our asset fleet’s trading in multiple marketplaces. Tailored tools for bid handling and market communication convinced us that Hansen Trade was the right market solution to meet our evolving needs. Hansen also has a deep knowledge of the electricity markets and offers valuable advice on everything from strategy to operations. With Hansen Trade, we can start trading operations seamlessly and ensure that we unlock the total value potential of all our assets.”
David Castree, Chief Customer Officer at Hansen, commented: “It is clear that Stockholm Exergi are visionaries in the sector. Their transition from a conventional city-based energy provider to an active power trader, their participation in COP27, plus the announced creation – supported by the European Innovation Fund – of a carbon-capture and storage facility prove that. As such, their choice of Hansen Trade as the strategic power trading platform is all the more consequential and a genuine endorsement of Hansen’s leadership Hansen in this important space. Hansen’s power trading platform empowers several energy companies across the Nordic region, with Skelleftea Kraft, Bixia, Vantaa Energy, Tampereen Sähkölaitos, Malarenergi and Jämtkraft, to name a few. Leveraging Hansen Trade, these organisations operate with unparalleled agility in a highly dynamic market.”
Part of the Hansen Suite for Energy & Utilities, and delivered as a cloud-based SaaS solution, Hansen Trade fully meets the flexibility and scalability demands of the evolving energy trading market.
For further information about Hansen Technologies, please visit www.hansencx.com.
About Hansen
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water, and communications industries. With its award-winning software portfolio, Hansen serves customers in over 80 countries, helping them create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
Stockholm Exergi
Stockholm Exergi is Stockholm’s energy provider. Using resource-efficient solutions, Stockholm Exergi ensures that the growing Stockholm region has access to electricity, heating, cooling, and waste services. The company provides heat to more than 800,000 residents, and its 3,000-kilometre-long district heating network forms the basis for the societal benefits that Stockholm Exergi creates with its customers and partners.
For more information, visit https://www.stockholmexergi.se/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425659483/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
